Immunomodulation as a novel treatment strategy for periodontal disease: a systematic review
Abstract
Background: Periodontal diseases (PDs) are globally prevalent and are associated with reduced quality of life and systemic health complications. Conventional therapy, involving professional mechanical plaque removal (PMPR) and oral hygiene instruction, faces limitations involving disease recurrence and patient factors. This systematic review explores immunomodulatory therapies as alternative or adjunctive treatments.
Method: MEDLINE (Ovid), EMBASE (Ovid), Cochrane Database of Systematic Reviews and MEDLINE (Web of Science) databases were searched on 9 June 2024. Two authors independently screened the articles using pre-specified inclusion and exclusion criteria, and findings were grouped by immunomodulatory agent.
Results: The search retrieved 2363 records, and 42 were included. Thirteen types of immunomodulatory agents were evaluated across cell lines, animal models of PD, and observational studies and clinical trials in humans. Several agents showed evidence of effects on inflammation and alveolar bone loss; however, the quality and consistency of evidence varied. Limited data suggest that longer treatment duration, alternative delivery methods, or combination approaches may enhance therapeutic outcomes.
Conclusion: Immunomodulatory agents show promise for the management of PD, including in patients with co-morbidities. However, clinical evidence in the context of conventional therapy and safety data remain limited. Further rigorous trials are needed to confirm efficacy,…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.